Activation of AML1-mediated transcription by MOZ and inhibition by the MOZ-CBP fusion protein
about
MOZ and MORF histone acetyltransferases interact with the Runt-domain transcription factor Runx2The human monocytic leukemia zinc finger histone acetyltransferase domain contains DNA-binding activity implicated in chromatin targetingRoles of HIPK1 and HIPK2 in AML1- and p300-dependent transcription, hematopoiesis and blood vessel formationMolecular architecture of quartet MOZ/MORF histone acetyltransferase complexesMOZ increases p53 acetylation and premature senescence through its complex formation with PMLMOZ-TIF2 inhibits transcription by nuclear receptors and p53 by impairment of CBP functionMOZ and MORF, two large MYSTic HATs in normal and cancer stem cellsTranscriptional regulation of the human MIP-1alpha promoter by RUNX1 and MOZKATs in cancer: functions and therapiesThe double PHD finger domain of MOZ/MYST3 induces -helical structure of the histone H3 tail to facilitate acetylation and methylation sampling and modificationCombinatorial readout of unmodified H3R2 and acetylated H3K14 by the tandem PHD finger of MOZ reveals a regulatory mechanism for HOXA9 transcriptionRegulation of KAT6 Acetyltransferases and Their Roles in Cell Cycle Progression, Stem Cell Maintenance, and Human DiseaseHistone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancyThe Role of Histone Acetyltransferases in Normal and Malignant HematopoiesisSUV39H1 interacts with AML1 and abrogates AML1 transactivity. AML1 is methylated in vivoNemo-like kinase suppresses a wide range of transcription factors, including nuclear factor-kappaBChanges in global gene expression during in vitro decidualization of rat endometrial stromal cellsHistone acetyltransferase MOZ acts as a co-activator of Nrf2-MafK and induces tumour marker gene expression during hepatocarcinogenesisMOZ is essential for maintenance of hematopoietic stem cellsMonocytic leukemia zinc finger protein is essential for the development of long-term reconstituting hematopoietic stem cellsPEBP2-beta/CBF-beta-dependent phosphorylation of RUNX1 and p300 by HIPK2: implications for leukemogenesisMethylation of RUNX1 by PRMT1 abrogates SIN3A binding and potentiates its transcriptional activity.Definitive hematopoiesis requires Runx1 C-terminal-mediated subnuclear targeting and transactivation.Genes encoding critical transcriptional activators for murine neural tube development and human spina bifida: a case-control study.Genomic analysis of individual differences in ethanol drinking: evidence for non-genetic factors in C57BL/6 mice.An efficient high-throughput screening method for MYST family acetyltransferases, a new class of epigenetic drug targets.SARS coronavirus 3b accessory protein modulates transcriptional activity of RUNX1b.Leukaemogenesis: more than mutant genesCrystallization and preliminary X-ray diffraction analysis of the BRPF1 bromodomain in complex with its H2AK5ac and H4K12ac histone-peptide ligands.Bromodomain-PHD finger protein 1 is critical for leukemogenesis associated with MOZ-TIF2 fusion.Molecular insights into the recognition of N-terminal histone modifications by the BRPF1 bromodomain.The MOZ histone acetyltransferase in epigenetic signaling and disease.The lysine acetyltransferase activator Brpf1 governs dentate gyrus development through neural stem cells and progenitors.MOZ-TIF2 alters cofactor recruitment and histone modification at the RARbeta2 promoter: differential effects of MOZ fusion proteins on CBP- and MOZ-dependent activators.KAT6A, a chromatin modifier from the 8p11-p12 amplicon is a candidate oncogene in luminal breast cancerPU.1-mediated upregulation of CSF1R is crucial for leukemia stem cell potential induced by MOZ-TIF2Requirement of clathrin heavy chain for p53-mediated transcription.Dominant mutations in KAT6A cause intellectual disability with recognizable syndromic features.De novo nonsense mutations in KAT6A, a lysine acetyl-transferase gene, cause a syndrome including microcephaly and global developmental delayRUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making
P2860
17bfaee89154f2f87da8dd983263e360f5c5e1d460eef22f067fe68d712928dbcab895fb14a34fec7765cd254d01e4432e3c2bdf79e527c22fc506f8867d71e32dfbc504ccaa958c0cb0f07487b6800f892ac7851b734ff99a64a9a1f23ca9cd03660d6ab0e49e7f5a2b977d9b4254886524a7c907adb5ecc23b4b7cb7766fd19832437e4e0aaa41b2751eeaf8b7ca4f1319b25ee6859163f288c4a2643d6cca
P248
Q24294814-CEFE34AF-529D-4C9D-8805-59571899321EQ24297050-F155F46C-3F51-4500-9D24-64E58C356C21Q24300183-DA0E2A4F-2A50-4D36-BEA6-E640B3FD28A4Q24312967-9B9FFD4B-D984-437C-A51D-ECF5E45FDBAAQ24319117-0A63753F-92A3-48A3-8D14-0F95EB5731E3Q24557551-8AA97865-FED9-4D22-A4DE-B31C2B7FF863Q24570117-7FF7E1C5-5F18-438E-B073-BD67754CCE49Q24671519-4B6197D6-EF99-419C-ABB6-63385867E858Q26859355-3371D057-DE56-4233-BB9B-5C7A3681CB24Q27680427-A69E5DE2-9A48-448B-9186-A2F8A4FF5A97Q27681246-B23825A4-74B6-456E-AF94-965D9E46F73EQ28079704-2D1DE1F3-26F5-4176-9AC0-1307B5B6B099Q28082536-A2346B3E-6D12-4A0E-91C8-7DD3CD708C5DQ28088295-C5D81A4F-1C84-457F-AC79-3495912117D1Q28201653-1E202B75-2143-45E7-B9C7-3E47F44606EFQ28238509-307471B8-77DE-4AB1-93BA-4170AE84B398Q28567241-3FC9EC91-4BB4-40E7-8477-C9A5883F0817Q28574325-B52FCA19-19F5-4672-9DC3-6E3596E17CD6Q28587906-2BC51345-F6E1-4213-AE88-33A195709480Q28590949-BD24077E-7758-4229-8D12-51D8B58A2BE7Q32884406-085E0D44-FA0F-4E1E-9A68-5559BF816C90Q32884501-FF96EFCD-07F4-4FF8-ADE1-B39B49FE472AQ33697682-AB05B05A-3D7C-4C01-9DE8-B9C4D46ECA26Q33713299-1BA5047F-E2F9-4E51-B4D8-6B40B3F0384FQ33940849-625E5CB6-F701-490B-AB57-A6A2C187334EQ34075283-0CB041B7-61EE-41A5-AE0C-18C8604B33D1Q34130454-C022EE44-DF8C-4935-A292-C19E7DBACFB4Q34275371-D0F4EB56-4C26-4E3D-BFE0-468F1ECB952AQ34299549-17D40381-CB79-4AFE-8D4F-386B1F7E48C2Q34386581-D9F5C5BE-72B0-4664-B151-0C8F61A8EBDEQ34391526-D81EF3C6-A9D3-4DBC-AD26-F4F8B9158C86Q34410314-12A1746A-544F-4FF2-858A-F196C0C69A37Q34466505-37734374-E4F5-4C16-873F-50F0AD913BBFQ34513687-662ED67F-8274-4F1B-995C-EF40993FF3F1Q34528297-D4F69F37-ED4F-41D4-8594-954C3480224CQ34577769-7D14B258-EA90-4825-9753-B6403173E1CBQ34650413-896F2FA3-D7DC-42D0-A329-F0EF9084437BQ35221418-2FF731DC-08F6-4E2A-93F2-FB25AC483D5FQ35221908-947564E4-79E3-447A-9B44-848885E3D121Q35642451-DFB14A4E-D43F-4281-A994-A986C8E80E9C
P2860
Activation of AML1-mediated transcription by MOZ and inhibition by the MOZ-CBP fusion protein
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
Activation of AML1-mediated tr ...... by the MOZ-CBP fusion protein
@ast
Activation of AML1-mediated tr ...... by the MOZ-CBP fusion protein
@en
Activation of AML1-mediated tr ...... by the MOZ-CBP fusion protein
@en-gb
Activation of AML1-mediated tr ...... by the MOZ-CBP fusion protein
@nl
type
label
Activation of AML1-mediated tr ...... by the MOZ-CBP fusion protein
@ast
Activation of AML1-mediated tr ...... by the MOZ-CBP fusion protein
@en
Activation of AML1-mediated tr ...... by the MOZ-CBP fusion protein
@en-gb
Activation of AML1-mediated tr ...... by the MOZ-CBP fusion protein
@nl
prefLabel
Activation of AML1-mediated tr ...... by the MOZ-CBP fusion protein
@ast
Activation of AML1-mediated tr ...... by the MOZ-CBP fusion protein
@en
Activation of AML1-mediated tr ...... by the MOZ-CBP fusion protein
@en-gb
Activation of AML1-mediated tr ...... by the MOZ-CBP fusion protein
@nl
P2093
P2860
P921
P356
P1433
P1476
Activation of AML1-mediated tr ...... by the MOZ-CBP fusion protein
@en
P2093
P2860
P304
P356
10.1093/EMBOJ/20.24.7184
P407
P577
2001-12-01T00:00:00Z